These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35298785)

  • 1. Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis.
    Cheng Y; Li T; Tan P; Du Y; Huang Z; Shi H; Cai T; Chen Y; Fu W
    Endocrine; 2022 May; 76(2):253-262. PubMed ID: 35298785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials.
    Calcaterra I; Lupoli R; Di Minno A; Di Minno MND
    Eur J Clin Invest; 2022 Nov; 52(11):e13841. PubMed ID: 35851450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials.
    Fogacci F; Norata GD; Toth PP; Arca M; Cicero AFG
    Curr Atheroscler Rep; 2020 May; 22(5):18. PubMed ID: 32458077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
    D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
    Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
    Prohaska TA; Alexander VJ; Karwatowska-Prokopczuk E; Tami J; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2023; 17(3):406-411. PubMed ID: 37164837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.
    Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S
    J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.
    Yang X; Lee SR; Choi YS; Alexander VJ; Digenio A; Yang Q; Miller YI; Witztum JL; Tsimikas S
    J Lipid Res; 2016 Apr; 57(4):706-13. PubMed ID: 26848137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volanesorsen: First Global Approval.
    Paik J; Duggan S
    Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
    Spagnuolo CM; Hegele RA
    Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
    Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
    N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A; Simental-Mendía LE; Mikhailidis DP; Pirro M; Banach M; Sirtori CR; Reiner Ž
    Ann Med; 2018 Nov; 50(7):565-575. PubMed ID: 30102092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy.
    Lightbourne M; Startzell M; Bruce KD; Brite B; Muniyappa R; Skarulis M; Shamburek R; Gharib AM; Ouwerkerk R; Walter M; Eckel RH; Brown RJ
    J Clin Lipidol; 2022; 16(6):850-862. PubMed ID: 36195542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia - spotlight on volanesorsen.
    Milonas D; Tziomalos K
    Expert Opin Investig Drugs; 2019 Apr; 28(4):389-394. PubMed ID: 30753100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
    Warden BA; Duell PB
    Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volanesorsen for treatment of familial chylomicronemia syndrome.
    Lazarte J; Hegele RA
    Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.
    Arca M; Hsieh A; Soran H; Rosenblit P; O'Dea L; Stevenson M
    Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):537-546. PubMed ID: 29889589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
    Esan O; Wierzbicki AS
    Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.